These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

113 related articles for article (PubMed ID: 23457034)

  • 1. Enhancing clinical outcomes in hepatocellular carcinoma.
    Abou-Alfa G
    Semin Liver Dis; 2013 Feb; 33 Suppl 1():S1. PubMed ID: 23457034
    [No Abstract]   [Full Text] [Related]  

  • 2. Multidisciplinary management of hepatocellular carcinoma: where are we today?
    Marrero JA
    Semin Liver Dis; 2013 Feb; 33 Suppl 1():S3-10. PubMed ID: 23457037
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Shaping the future management of hepatocellular carcinoma.
    Abou-Alfa G; Colombo M
    Semin Liver Dis; 2013 Feb; 33 Suppl 1():S20-3. PubMed ID: 23457036
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical and molecular insights into the hepatocellular carcinoma tumour marker des-γ-carboxyprothrombin.
    Inagaki Y; Tang W; Makuuchi M; Hasegawa K; Sugawara Y; Kokudo N
    Liver Int; 2011 Jan; 31(1):22-35. PubMed ID: 20874725
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Emerging targeted strategies in advanced hepatocellular carcinoma.
    Finn RS
    Semin Liver Dis; 2013 Feb; 33 Suppl 1():S11-9. PubMed ID: 23457035
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Hepatocellular carcinoma: epidemiology, surveillance, and diagnosis.
    Sherman M
    Semin Liver Dis; 2010 Feb; 30(1):3-16. PubMed ID: 20175029
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Evaluation of prognosis and recurrence of hepatocellular carcinoma treated from 1988 to 2002 at Department of Medicine III, Kyushu University Hospital].
    Arimura E; Nakamuta M; Kotoh K; Morizono S; Fukutomi M; Ohta S; Enjoji M; Sakai H; Nawata H
    Fukuoka Igaku Zasshi; 2004 Aug; 95(8):195-200. PubMed ID: 15552961
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Fibrolamellar hepatocellular carcinoma].
    Renard V; Merlet C; Hagege H
    Ann Gastroenterol Hepatol (Paris); 1991 Dec; 27(7):314-21. PubMed ID: 1665324
    [No Abstract]   [Full Text] [Related]  

  • 9. Expression and prognostic role of pan-Ras, Raf-1, pMEK1 and pERK1/2 in patients with hepatocellular carcinoma.
    Chen L; Shi Y; Jiang CY; Wei LX; Wang YL; Dai GH
    Eur J Surg Oncol; 2011 Jun; 37(6):513-20. PubMed ID: 21324414
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Hepatocellular carcinoma.
    Marrero JA
    Curr Opin Gastroenterol; 2006 May; 22(3):248-53. PubMed ID: 16550039
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Molecular markers and hepatocellular carcinoma: lending a helping hand in liver transplantation?
    Dai Z; Yu L; Zhou J; Qiu SJ; Fan J
    Expert Rev Gastroenterol Hepatol; 2009 Jun; 3(3):211-3. PubMed ID: 19485802
    [No Abstract]   [Full Text] [Related]  

  • 12. Hepatocellular carcinoma in 2011 and beyond: from the pathogenesis to molecular targeted therapy.
    Kudo M
    Oncology; 2011; 81 Suppl 1():1-10. PubMed ID: 22212929
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Chemoembolization and bland embolization: a critical appraisal.
    Befeler AS
    Clin Liver Dis; 2005 May; 9(2):287-300, vii. PubMed ID: 15831274
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [The role of tumor markers in the diagnosis and follow-up of liver tumors].
    Ottó S
    Orv Hetil; 2004 Feb; 145(7 Suppl 1):385-7. PubMed ID: 15049057
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Hepatocellular carcinoma.
    Naugler WE; Schwartz JM
    Dis Mon; 2008 Jul; 54(7):432-44. PubMed ID: 18570913
    [No Abstract]   [Full Text] [Related]  

  • 16. [Primary liver tumors in children].
    Vos A; Kuijper CF
    Ned Tijdschr Geneeskd; 1995 Sep; 139(38):1918-22. PubMed ID: 7477530
    [No Abstract]   [Full Text] [Related]  

  • 17. Hepatocellular carcinoma in the United States. Prognostic features, treatment outcome, and survival.
    Stuart KE; Anand AJ; Jenkins RL
    Cancer; 1996 Jun; 77(11):2217-22. PubMed ID: 8635087
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Decreased expression of XPO4 is associated with poor prognosis in hepatocellular carcinoma.
    Liang XT; Pan K; Chen MS; Li JJ; Wang H; Zhao JJ; Sun JC; Chen YB; Ma HQ; Wang QJ; Xia JC
    J Gastroenterol Hepatol; 2011 Mar; 26(3):544-9. PubMed ID: 21332550
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Hepatocellular carcinoma: current trends in worldwide epidemiology, risk factors, diagnosis and therapeutics.
    Shariff MI; Cox IJ; Gomaa AI; Khan SA; Gedroyc W; Taylor-Robinson SD
    Expert Rev Gastroenterol Hepatol; 2009 Aug; 3(4):353-67. PubMed ID: 19673623
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Latest developments in targeted therapy for hepatocellular carcinoma.
    Montella L; Addeo R; Caraglia M; Del Prete S
    Expert Rev Anticancer Ther; 2010 Oct; 10(10):1635-46. PubMed ID: 20942634
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.